Metformin and glimepiride prevent amyloid pathology by decreasing APP and BACE1 expression, increasing IDE levels, and reducing Aß42 deposition, also reversing tau hyperphosphorylation in both PreDM and T2D models [187–190]. Here, BACE1 is linked to type 2 diabetes mellitus.